A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice release_s6n26xvafvcvvp2esjez3yl3m4

by Vincenzo Mirone, Ferdinando Fusco, Fabio Parazzini, Alessandro Zucchi

Published in Archivio Italiano di Urologia e Andrologia by PAGEPress Publications.

2016   Volume 88, p128


Introduction: PDE5 inhibitors are the firstline treatment for erectile dysfunction. Although all these drugs share the same mechanism of action, each agent could have different characteristics in terms of selectivity, pharmacokinetics and tolerability profile. Materials and Methods: This manuscript illustrates a project, undertaken by the Italian Society of Urology in order to obtain a "snapshot" of the experience of Italian urologists with the use of PDE5 inhibitors in the clinical practice. This project included a survey, targeting a sample of 136 Italian urologists experienced in the treatment of ED, and the organization of a conference of experts who, based on the findings of the survey, the scientific literature and the clinical experience, would define some recommendations for the use of PDE5 inhibitors in clinical practice with a particular focus on Avanafil, the most recent drug in this class. Results: The following recommendations on the use of Avanafil were issued: 1) In patients who are candidates for the use of Avanafil, it is advisable to use the 200-mg dose from the first administration; 2) When used at the highest dose (200 mg), Avanafil shows a favourable tolerability profile with an efficacy similar to that of other agents; 3) The patient should be instructed to take Avanafil on an empty stomach, i.e., 30-45 minutes before or 2 hours after a meal; 4) The efficacy window of Avanafil is between 30 minutes and 6 hours after dosing, which qualifies this molecule as a new drug with an intermediate duration of action; 5) Avanafil at a dose of 50-100 mg/day may be a therapeutic option in chronic rehabilitation. Conclusions: Among PDE5 inhibitors, Avanafil is a new agent with an intermediate duration of action, characterized by high efficacy and good tolerability even at the highest dose (200 mg).
In application/xml+jats format

Archived Files and Locations

application/pdf  523.4 kB
www.pagepressjournals.org (web)
web.archive.org (webarchive)
Read Archived PDF
Type  article-journal
Stage   published
Date   2016-07-04
DOI  10.4081/aiua.2016.2.128
PubMed  27377089
Wikidata  Q39633189
Container Metadata
Open Access Publication
Not in Keepers Registry
ISSN-L:  1124-3562
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 5c671ca5-a075-4375-b4dc-ffc9bac7356c